#bluebird bio Inc (BLUE) - Prohost Biotech

Revisiting Bluebird Bio Inc

Bluebird Bio Inc For investors who thought that bluebird bio Inc ( BLUE ) stock price jumped up from less than $1, to over $7, we inform those who didn't know and remind those who knew that on Decembe...

P

Prohost Biotech

Dec 18, 2024

Stocks Outperforming Today

January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata Pharmaceuticals ( RETA ) bluebird bio Inc ( BLUE ) And Vertex Pharmaceuticals ( VRTX ) ...

P

Prohost Biotech

Jan 5, 2023

1m

0

News & Comments

From bluebird bio: FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy

FDA Approves bluebird bio Product Skysona for Early, Active CALD SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fat...

P

Prohost Biotech

Sep 19, 2022

bluebird bio Receives Approval for its Gene Therapy SKYSONA™ for Young People with Early CALD Without a Matched Sibling Donor

bluebird bio Receives EC Approval for bluebird bio ( BLUE ) announced that the European Commission ( EC ) has granted marketing authorization of SKYSONA™ (elivaldogene autotemcel, Lenti-D™) one-tim...

P

Prohost Biotech

Jul 22, 2021

Important News and Results from Two Companies in the Prohost Portfolio

Important News and Results from Akero Therapeutics Akero Therapeutics ( AKRO ) announced that full results of the main portion of its Phase 2a BALANCED trial in biopsy-confirmed NASH patients with F1-...

P

Prohost Biotech

Jul 9, 2021

The FDA Lifts the Clinical Holds on bluebird bio Gene Therapies in Clinical Trials

Clinical Holds on bluebird bio Gene Therapies were Lifted by the FDA The U.S. FDA has lifted the clinical holds on the bluebird bio ( BLUE ) Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobi...

P

Prohost Biotech

Jun 7, 2021

Your Questions, Our Answers

Prohost Portfolio PLUS (formerly The Week in Review) Your Questions, Our Answers In the upcoming issues of Prohost Portfolio PLUS, as with all our Tables, we will include observations and target chang...

P

Prohost Biotech

Mar 28, 2021

bluebird bio Provides Updated Findings of AML in LentiGlobin for SCD Gene Therapy Program

Updated Findings from bluebird bio bluebird bio analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in a clinical study of LentiGlobin for SCD bluebird bio initiated a process...

P

Prohost Biotech

Mar 10, 2021

bluebird bio Temporarily Suspends Studies of LentiGlobin Gene Therapy for SCD. See Also: Cellectis is Outperforming

bluebird bio Suspends LentiGlobin Studies bluebird bio ( BLUE ) placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD), bb1111, on a tem...

P

Prohost Biotech

Feb 17, 2021

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

bluebird bio Decision to Separate its Businesses bluebird bio ( BLUE ) will retain focus on its severe genetic disease ( SGD ) and will launch its oncology business ( Oncology Newco ) as a new entity...

P

Prohost Biotech

Jan 14, 2021

The Biotechnology Industry

Prohost Letter #443 The Biotechnology Industry The Biotechnology Industry revolutionized the arts of life sciences with accomplishments promising a tremendous improvement in the treatment of chronic,...

P

Prohost Biotech

Dec 8, 2020

About bluebird bio

bluebird bio bluebird bio ( BLUE ) financial results and business highlights for the third quarter 2020 are important to be aware of when volatility and negative analysis lack common sense. The stock...

P

Prohost Biotech

Nov 10, 2020

Bristol-Myers Squibb and bluebird bio Product Ide-Cel, Bb2121 and the FDA Refusal Letter. What Do We Expect?

Bristol-Myers Squibb and bluebird bio Bristol-Myers Squibb ( BMY ) and bluebird bio ( BLUE ) received a Refusal to File letter from the United States FDA regarding the Biologics License Application (...

P

Prohost Biotech

May 13, 2020

Let the Market Plummet But Not Our stocks

The Market May be Plummeting But Prohost Picks are Not Biotech stocks had a strong start, but the gains disappeared in many stocks as the market demonstrated bearishness following a long-lasting rally...

P

Prohost Biotech

Dec 3, 2019

RegenxBio is Rebounding. See Also: A Scientifically Valuable Agreement Between CRISPR Therapeutics and KSQ Therapeutics

RegenxBio Rebounding RegenxBio ( RGNX ) has the viral vectors which could safely deliver genes into the cells. The firm has improved the adeno-associated viruses making them safe and effective gene de...

P

Prohost Biotech

Oct 15, 2019

1m

0

News & Comments

Novartis: Plenty of Good News. See Also: Topics We Will Address in an Upcoming Week in Review

Stock Market Volatility Stocks can move up and down for various reasons but not all of them have anything to do with the real value of the firms. As a matter of fact, almost all stocks outperform for...

P

Prohost Biotech

Oct 11, 2019

What Are We Experiencing Now?

Prohost Letter #436 What Are We Experiencing Now? The bizarre market underperformance progressing rather than regressing and the good economy and the employment gains are the least utilized factors af...

P

Prohost Biotech

Oct 4, 2019

The Value of the Biotech Companies Continued

Prohost Letter #435 The Value of the Biotech Companies A Continuation of Prohost Letter #434 A Recap The biotech near and long-term values, we insist, must be based on the firms’ scientific capabiliti...

P

Prohost Biotech

Sep 23, 2019

At bluebird bio an Investigational Gene Therapy is Demonstrating Promising Results

bluebird bio Has Promising Results from Its Lenti-D Gene Therapy for CALD Good results have come from bluebird bio’s ( BLUE ) updated results in the clinical development program for its investigation...

P

Prohost Biotech

Sep 20, 2019

About RegenxBio's Agreement with Clearside Biomedical and More

Diseases of the Back of the Eye Diseases of the back of the eye, such as: age-related wet macular degeneration, diabetic retinopathy and diabetic macular edema, are currently managed with injections o...

P

Prohost Biotech

Sep 10, 2019

1m

0